Dr. Hoenle AG Stock
€19.50
Your prediction
Dr. Hoenle AG Stock
Pros and Cons of Dr. Hoenle AG in the next few years
Pros
Cons
Performance of Dr. Hoenle AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Dr. Hoenle AG | -2.030% | -2.500% | -1.763% | -2.256% | 11.748% | -59.544% | -62.644% |
| Pfeiffer Vacuum | -0.130% | 0.389% | -0.129% | 2.246% | 0.389% | -5.610% | 9.709% |
| Technotrans AG NA O.N. | 2.360% | -3.571% | 23.782% | -20.879% | -0.461% | -16.279% | -6.291% |
| NORMA Group SE | -1.650% | 3.001% | 6.897% | 0.313% | 19.676% | -57.346% | -51.709% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Dr. Hoenle AG, a company within the Machinery, Equipment, and Components industry, exhibit mixed performance over the past few years. While the company has shown stability in some areas, there have been notable decreases in certain key financial metrics. In the following analysis, we will explore in depth the pros and cons of the company's financial performance.
*Pros: *
Stable Gross Profit: Dr. Hoenle AG has maintained a stable gross profit in recent years, demonstrating the company's ability to generate revenue from its core business operations consistently.
Comments
News
Hönle Group has a moderate start to the new financial year and confirms the outlook for the year as a whole
Gilching, 26 February 2024
- Revenue in the first quarter of €23.8 million below the previous year's figure of €27.6 million due to the weak market environment
- Operating
